Metoprolol Tartrate Accord Healthcare (Metoprolol Tartrate)

The drug selectively blocks β1‑adrenergic receptors in the heart, decreasing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, reduced contractile force, and lower cardiac output, which together help to lower blood pressure and lessen myocardial oxygen demand.

The appropriate dose is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any co‑existing health issues. Dosage may be started low and adjusted gradually; patients should follow the prescriber’s instructions exactly.

Safety data for Metoprolol Tartrate in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Healthcare providers weigh potential benefits against risks before prescribing to pregnant or nursing women.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol Tartrate is a β1‑selective blocker, offering cardiac‑focused effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Its pharmacokinetic profile allows flexible dosing, but clinicians choose the most appropriate beta blocker based on individual patient characteristics and comorbidities.

Store the tablets at room temperature, below 25 °C, in the original container. Protect them from moisture and direct sunlight to maintain stability throughout the product’s shelf life.

Metoprolol Tartrate is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water; they are not intended for crushing or chewing unless specifically advised.

Serious adverse events can include severe bradycardia, heart block, and bronchospasm, especially in patients with underlying respiratory disease. Prompt medical attention is required if symptoms such as fainting, extreme fatigue, or difficulty breathing occur.

Patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe sinus bradycardia, second‑ or third‑degree heart block without a pacemaker, or uncontrolled asthma/COPD should avoid this medication unless a specialist advises otherwise.